Financhill
Sell
21

BDRX Quote, Financials, Valuation and Earnings

Last price:
$1.06
Seasonality move :
-7.03%
Day range:
$1.14 - $1.22
52-week range:
$1.11 - $41.50
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
1.20x
P/B ratio:
0.28x
Volume:
2.3M
Avg. volume:
2.4M
1-year change:
-95.53%
Market cap:
$2.9M
Revenue:
$474.1K
EPS (TTM):
-$74.60

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
BDRX
Biodexa Pharmaceuticals PLC
-- -- -- -- $17.94
ADAP
Adaptimmune Therapeutics PLC
$6.6M -$0.17 -91.39% -8.33% $1.58
AUTL
Autolus Therapeutics PLC
$2M -$0.25 -80.39% -10.73% $9.97
MREO
Mereo BioPharma Group PLC
$15.9M -$0.01 -100% -87.66% $7.66
NCNA
NuCana PLC
-- -$0.01 -- -99.69% $104.00
VRNA
Verona Pharma PLC
$54.8M -$0.03 -- -99.24% $94.10
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
BDRX
Biodexa Pharmaceuticals PLC
$1.15 $17.94 $2.9M -- $0.00 0% 1.20x
ADAP
Adaptimmune Therapeutics PLC
$0.28 $1.58 $74.3M -- $0.00 0% 0.40x
AUTL
Autolus Therapeutics PLC
$1.57 $9.97 $417.8M -- $0.00 0% --
MREO
Mereo BioPharma Group PLC
$2.18 $7.66 $346.6M -- $0.00 0% --
NCNA
NuCana PLC
$0.04 $104.00 $236.2K -- $0.00 0% --
VRNA
Verona Pharma PLC
$75.61 $94.10 $6.4B -- $0.00 0% --
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
BDRX
Biodexa Pharmaceuticals PLC
-- 2.357 -- 1.20x
ADAP
Adaptimmune Therapeutics PLC
-211.44% 3.631 50.03% 1.57x
AUTL
Autolus Therapeutics PLC
-- 1.803 -- 8.74x
MREO
Mereo BioPharma Group PLC
-- 0.393 -- --
NCNA
NuCana PLC
-- -0.390 -- --
VRNA
Verona Pharma PLC
51.62% 0.242 4.47% 8.30x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
BDRX
Biodexa Pharmaceuticals PLC
-- -- -160.77% -160.77% -- --
ADAP
Adaptimmune Therapeutics PLC
$6.4M -$44.1M -107.36% -199.63% -619.47% -$67.8M
AUTL
Autolus Therapeutics PLC
-$9M -$65.2M -49.92% -49.92% -643.43% -$83.8M
MREO
Mereo BioPharma Group PLC
-- -$11M -- -- -- -$8.6M
NCNA
NuCana PLC
-- -$1.6M -- -- -- -$9.3M
VRNA
Verona Pharma PLC
$72.8M -$10.3M -51.07% -85.84% -8.34% -$12.1M

Biodexa Pharmaceuticals PLC vs. Competitors

  • Which has Higher Returns BDRX or ADAP?

    Adaptimmune Therapeutics PLC has a net margin of -- compared to Biodexa Pharmaceuticals PLC's net margin of -653.18%. Biodexa Pharmaceuticals PLC's return on equity of -160.77% beat Adaptimmune Therapeutics PLC's return on equity of -199.63%.

    Company Gross Margin Earnings Per Share Invested Capital
    BDRX
    Biodexa Pharmaceuticals PLC
    -- -- $6M
    ADAP
    Adaptimmune Therapeutics PLC
    87.93% -$0.18 -$12M
  • What do Analysts Say About BDRX or ADAP?

    Biodexa Pharmaceuticals PLC has a consensus price target of $17.94, signalling upside risk potential of 1460.34%. On the other hand Adaptimmune Therapeutics PLC has an analysts' consensus of $1.58 which suggests that it could grow by 462.34%. Given that Biodexa Pharmaceuticals PLC has higher upside potential than Adaptimmune Therapeutics PLC, analysts believe Biodexa Pharmaceuticals PLC is more attractive than Adaptimmune Therapeutics PLC.

    Company Buy Ratings Hold Ratings Sell Ratings
    BDRX
    Biodexa Pharmaceuticals PLC
    1 0 0
    ADAP
    Adaptimmune Therapeutics PLC
    3 3 0
  • Is BDRX or ADAP More Risky?

    Biodexa Pharmaceuticals PLC has a beta of 1.154, which suggesting that the stock is 15.371% more volatile than S&P 500. In comparison Adaptimmune Therapeutics PLC has a beta of 2.857, suggesting its more volatile than the S&P 500 by 185.668%.

  • Which is a Better Dividend Stock BDRX or ADAP?

    Biodexa Pharmaceuticals PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Adaptimmune Therapeutics PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Biodexa Pharmaceuticals PLC pays -- of its earnings as a dividend. Adaptimmune Therapeutics PLC pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios BDRX or ADAP?

    Biodexa Pharmaceuticals PLC quarterly revenues are --, which are smaller than Adaptimmune Therapeutics PLC quarterly revenues of $7.3M. Biodexa Pharmaceuticals PLC's net income of -- is lower than Adaptimmune Therapeutics PLC's net income of -$47.6M. Notably, Biodexa Pharmaceuticals PLC's price-to-earnings ratio is -- while Adaptimmune Therapeutics PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Biodexa Pharmaceuticals PLC is 1.20x versus 0.40x for Adaptimmune Therapeutics PLC. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    BDRX
    Biodexa Pharmaceuticals PLC
    1.20x -- -- --
    ADAP
    Adaptimmune Therapeutics PLC
    0.40x -- $7.3M -$47.6M
  • Which has Higher Returns BDRX or AUTL?

    Autolus Therapeutics PLC has a net margin of -- compared to Biodexa Pharmaceuticals PLC's net margin of -781.13%. Biodexa Pharmaceuticals PLC's return on equity of -160.77% beat Autolus Therapeutics PLC's return on equity of -49.92%.

    Company Gross Margin Earnings Per Share Invested Capital
    BDRX
    Biodexa Pharmaceuticals PLC
    -- -- $6M
    AUTL
    Autolus Therapeutics PLC
    -99.86% -$0.26 $371.1M
  • What do Analysts Say About BDRX or AUTL?

    Biodexa Pharmaceuticals PLC has a consensus price target of $17.94, signalling upside risk potential of 1460.34%. On the other hand Autolus Therapeutics PLC has an analysts' consensus of $9.97 which suggests that it could grow by 534.82%. Given that Biodexa Pharmaceuticals PLC has higher upside potential than Autolus Therapeutics PLC, analysts believe Biodexa Pharmaceuticals PLC is more attractive than Autolus Therapeutics PLC.

    Company Buy Ratings Hold Ratings Sell Ratings
    BDRX
    Biodexa Pharmaceuticals PLC
    1 0 0
    AUTL
    Autolus Therapeutics PLC
    7 0 0
  • Is BDRX or AUTL More Risky?

    Biodexa Pharmaceuticals PLC has a beta of 1.154, which suggesting that the stock is 15.371% more volatile than S&P 500. In comparison Autolus Therapeutics PLC has a beta of 1.767, suggesting its more volatile than the S&P 500 by 76.723%.

  • Which is a Better Dividend Stock BDRX or AUTL?

    Biodexa Pharmaceuticals PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Autolus Therapeutics PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Biodexa Pharmaceuticals PLC pays -- of its earnings as a dividend. Autolus Therapeutics PLC pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios BDRX or AUTL?

    Biodexa Pharmaceuticals PLC quarterly revenues are --, which are smaller than Autolus Therapeutics PLC quarterly revenues of $9M. Biodexa Pharmaceuticals PLC's net income of -- is lower than Autolus Therapeutics PLC's net income of -$70.2M. Notably, Biodexa Pharmaceuticals PLC's price-to-earnings ratio is -- while Autolus Therapeutics PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Biodexa Pharmaceuticals PLC is 1.20x versus -- for Autolus Therapeutics PLC. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    BDRX
    Biodexa Pharmaceuticals PLC
    1.20x -- -- --
    AUTL
    Autolus Therapeutics PLC
    -- -- $9M -$70.2M
  • Which has Higher Returns BDRX or MREO?

    Mereo BioPharma Group PLC has a net margin of -- compared to Biodexa Pharmaceuticals PLC's net margin of --. Biodexa Pharmaceuticals PLC's return on equity of -160.77% beat Mereo BioPharma Group PLC's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    BDRX
    Biodexa Pharmaceuticals PLC
    -- -- $6M
    MREO
    Mereo BioPharma Group PLC
    -- -$0.10 --
  • What do Analysts Say About BDRX or MREO?

    Biodexa Pharmaceuticals PLC has a consensus price target of $17.94, signalling upside risk potential of 1460.34%. On the other hand Mereo BioPharma Group PLC has an analysts' consensus of $7.66 which suggests that it could grow by 251.6%. Given that Biodexa Pharmaceuticals PLC has higher upside potential than Mereo BioPharma Group PLC, analysts believe Biodexa Pharmaceuticals PLC is more attractive than Mereo BioPharma Group PLC.

    Company Buy Ratings Hold Ratings Sell Ratings
    BDRX
    Biodexa Pharmaceuticals PLC
    1 0 0
    MREO
    Mereo BioPharma Group PLC
    6 0 0
  • Is BDRX or MREO More Risky?

    Biodexa Pharmaceuticals PLC has a beta of 1.154, which suggesting that the stock is 15.371% more volatile than S&P 500. In comparison Mereo BioPharma Group PLC has a beta of 0.465, suggesting its less volatile than the S&P 500 by 53.542%.

  • Which is a Better Dividend Stock BDRX or MREO?

    Biodexa Pharmaceuticals PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Mereo BioPharma Group PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Biodexa Pharmaceuticals PLC pays -- of its earnings as a dividend. Mereo BioPharma Group PLC pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios BDRX or MREO?

    Biodexa Pharmaceuticals PLC quarterly revenues are --, which are smaller than Mereo BioPharma Group PLC quarterly revenues of --. Biodexa Pharmaceuticals PLC's net income of -- is lower than Mereo BioPharma Group PLC's net income of -$12.9M. Notably, Biodexa Pharmaceuticals PLC's price-to-earnings ratio is -- while Mereo BioPharma Group PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Biodexa Pharmaceuticals PLC is 1.20x versus -- for Mereo BioPharma Group PLC. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    BDRX
    Biodexa Pharmaceuticals PLC
    1.20x -- -- --
    MREO
    Mereo BioPharma Group PLC
    -- -- -- -$12.9M
  • Which has Higher Returns BDRX or NCNA?

    NuCana PLC has a net margin of -- compared to Biodexa Pharmaceuticals PLC's net margin of --. Biodexa Pharmaceuticals PLC's return on equity of -160.77% beat NuCana PLC's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    BDRX
    Biodexa Pharmaceuticals PLC
    -- -- $6M
    NCNA
    NuCana PLC
    -- -$0.32 --
  • What do Analysts Say About BDRX or NCNA?

    Biodexa Pharmaceuticals PLC has a consensus price target of $17.94, signalling upside risk potential of 1460.34%. On the other hand NuCana PLC has an analysts' consensus of $104.00 which suggests that it could grow by 266566.67%. Given that NuCana PLC has higher upside potential than Biodexa Pharmaceuticals PLC, analysts believe NuCana PLC is more attractive than Biodexa Pharmaceuticals PLC.

    Company Buy Ratings Hold Ratings Sell Ratings
    BDRX
    Biodexa Pharmaceuticals PLC
    1 0 0
    NCNA
    NuCana PLC
    0 1 0
  • Is BDRX or NCNA More Risky?

    Biodexa Pharmaceuticals PLC has a beta of 1.154, which suggesting that the stock is 15.371% more volatile than S&P 500. In comparison NuCana PLC has a beta of 1.639, suggesting its more volatile than the S&P 500 by 63.921%.

  • Which is a Better Dividend Stock BDRX or NCNA?

    Biodexa Pharmaceuticals PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NuCana PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Biodexa Pharmaceuticals PLC pays -- of its earnings as a dividend. NuCana PLC pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios BDRX or NCNA?

    Biodexa Pharmaceuticals PLC quarterly revenues are --, which are smaller than NuCana PLC quarterly revenues of --. Biodexa Pharmaceuticals PLC's net income of -- is lower than NuCana PLC's net income of -$836.1K. Notably, Biodexa Pharmaceuticals PLC's price-to-earnings ratio is -- while NuCana PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Biodexa Pharmaceuticals PLC is 1.20x versus -- for NuCana PLC. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    BDRX
    Biodexa Pharmaceuticals PLC
    1.20x -- -- --
    NCNA
    NuCana PLC
    -- -- -- -$836.1K
  • Which has Higher Returns BDRX or VRNA?

    Verona Pharma PLC has a net margin of -- compared to Biodexa Pharmaceuticals PLC's net margin of -21.4%. Biodexa Pharmaceuticals PLC's return on equity of -160.77% beat Verona Pharma PLC's return on equity of -85.84%.

    Company Gross Margin Earnings Per Share Invested Capital
    BDRX
    Biodexa Pharmaceuticals PLC
    -- -- $6M
    VRNA
    Verona Pharma PLC
    95.53% -$0.16 $468.3M
  • What do Analysts Say About BDRX or VRNA?

    Biodexa Pharmaceuticals PLC has a consensus price target of $17.94, signalling upside risk potential of 1460.34%. On the other hand Verona Pharma PLC has an analysts' consensus of $94.10 which suggests that it could grow by 24.45%. Given that Biodexa Pharmaceuticals PLC has higher upside potential than Verona Pharma PLC, analysts believe Biodexa Pharmaceuticals PLC is more attractive than Verona Pharma PLC.

    Company Buy Ratings Hold Ratings Sell Ratings
    BDRX
    Biodexa Pharmaceuticals PLC
    1 0 0
    VRNA
    Verona Pharma PLC
    7 0 0
  • Is BDRX or VRNA More Risky?

    Biodexa Pharmaceuticals PLC has a beta of 1.154, which suggesting that the stock is 15.371% more volatile than S&P 500. In comparison Verona Pharma PLC has a beta of 0.206, suggesting its less volatile than the S&P 500 by 79.434%.

  • Which is a Better Dividend Stock BDRX or VRNA?

    Biodexa Pharmaceuticals PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Verona Pharma PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Biodexa Pharmaceuticals PLC pays -- of its earnings as a dividend. Verona Pharma PLC pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios BDRX or VRNA?

    Biodexa Pharmaceuticals PLC quarterly revenues are --, which are smaller than Verona Pharma PLC quarterly revenues of $76.3M. Biodexa Pharmaceuticals PLC's net income of -- is lower than Verona Pharma PLC's net income of -$16.3M. Notably, Biodexa Pharmaceuticals PLC's price-to-earnings ratio is -- while Verona Pharma PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Biodexa Pharmaceuticals PLC is 1.20x versus -- for Verona Pharma PLC. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    BDRX
    Biodexa Pharmaceuticals PLC
    1.20x -- -- --
    VRNA
    Verona Pharma PLC
    -- -- $76.3M -$16.3M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Is Apple Stock Undervalued or Overvalued?
Is Apple Stock Undervalued or Overvalued?

For many years, Apple (NASDAQ:AAPL) was just about the perfect…

Where Will Palo Alto Networks Stock Be in 5 Years?
Where Will Palo Alto Networks Stock Be in 5 Years?

You know those companies that just refuse to slow down…

UPS Stock Forecast: Is the 6.9% Dividend Too Good to Be True?
UPS Stock Forecast: Is the 6.9% Dividend Too Good to Be True?

Parcel delivery giant UPS (NYSE:UPS) has seen its fair share…

Stock Ideas

Buy
70
Is MSFT Stock a Buy?

Market Cap: $3.4T
P/E Ratio: 39x

Buy
68
Is NVDA Stock a Buy?

Market Cap: $3.3T
P/E Ratio: 46x

Sell
39
Is AAPL Stock a Buy?

Market Cap: $3T
P/E Ratio: 33x

Alerts

Buy
84
SBET alert for May 28

SharpLink Gaming [SBET] is down 18.03% over the past day.

Buy
58
TNXP alert for May 28

Tonix Pharmaceuticals Holding [TNXP] is up 1.57% over the past day.

Sell
37
ATS alert for May 28

ATS [ATS] is down 1.27% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock